Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Nabriva Therapeutics Plc (NBRV)

Nabriva Therapeutics Plc (NBRV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 57,295
  • Shares Outstanding, K 30,639
  • Annual Sales, $ 28,900 K
  • Annual Income, $ -49,450 K
  • 60-Month Beta 1.60
  • Price/Sales 0.13
  • Price/Cash Flow N/A
  • Price/Book 2.17
Trade NBRV with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 191.47%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 914.90% on 05/04/22
  • IV Low 0.00% on 02/02/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 0
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 73
  • Open Int (30-Day) 212

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -3.91
  • Number of Estimates 1
  • High Estimate -3.91
  • Low Estimate -3.91
  • Prior Year -6.00
  • Growth Rate Est. (year over year) +34.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2150 +53.91%
on 01/09/23
2.3800 -21.43%
on 01/05/23
-0.1300 (-6.50%)
since 01/03/23
3-Month
1.2150 +53.91%
on 01/09/23
2.8700 -34.84%
on 11/28/22
-0.3950 (-17.44%)
since 11/03/22
52-Week
1.2150 +53.91%
on 01/09/23
13.5000 -86.15%
on 02/07/22
-9.3275 (-83.30%)
since 02/03/22

Most Recent Stories

More News
Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study

Nabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous Xenleta (lefamulin) in adult patients with cystic fibrosis. Shares down.

ANGN : 0.6728 (unch)
NBRV : 1.8700 (+1.63%)
ASLN : 0.7269 (-2.06%)
IMCR : 64.29 (+1.21%)
All You Need to Know About Nabriva Therapeutics AG (NBRV) Rating Upgrade to Buy

Nabriva Therapeutics AG (NBRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

NBRV : 1.8700 (+1.63%)
Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

- Topline Data Expected First Quarter 2023 -...

NBRV : 1.8700 (+1.63%)
Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

-Net Product Sales of $8.7M Grew 25% versus Q2 2021- -SIVEXTRO Prescription Demand Grew 28% versus Q2 2021- -Conference Call Today at 4:30 p.m. Eastern...

NBRV : 1.8700 (+1.63%)
Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022

DUBLIN, Ireland and FORT WASHINGTON, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged...

NBRV : 1.8700 (+1.63%)
Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticals

DUBLIN, Ireland and FORT WASHINGTON, Pa., July 18, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged...

NBRV : 1.8700 (+1.63%)
Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference

DUBLIN, Ireland, May 13, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization...

NBRV : 1.8700 (+1.63%)
Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

-SIVEXTRO Distribution and Promotion Agreement with Merck Formally Extended Through at Least 2026- -SIVEXTRO Prescription Demand Grew 10% Versus Q1...

NBRV : 1.8700 (+1.63%)
Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026

DUBLIN, Ireland and FORT WASHINGTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) --  Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged...

NBRV : 1.8700 (+1.63%)
Nabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022

DUBLIN, Ireland and FORT WASHINGTON, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged...

NBRV : 1.8700 (+1.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins,...

See More

Key Turning Points

3rd Resistance Point 2.1165
2nd Resistance Point 2.0433
1st Resistance Point 1.9566
Last Price 1.8700
1st Support Level 1.7967
2nd Support Level 1.7235
3rd Support Level 1.6368

See More

52-Week High 13.5000
Fibonacci 61.8% 8.8071
Fibonacci 50% 7.3575
Fibonacci 38.2% 5.9079
Last Price 1.8700
52-Week Low 1.2150

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar